8-K: Pulse Biosciences Launches Rights Offering to Raise Up to $60 Million

Pulse Biosciences has commenced a rights offering to raise up to $60 million by offering units to existing shareholders.

Summary

• Pulse Biosciences has initiated a rights offering to raise up to $60 million.
• The offering provides existing shareholders with non-transferable subscription rights to purchase units.
• Each unit consists of one share of common stock and two warrants.
• The price per unit will be the lesser of $10 or the volume-weighted average price of the common stock over the ten trading days leading up to the expiration date.
• The rights offering expires on June 26, 2024, at 5:00 p.m. Eastern Time.
• The company will sell up to 6,000,000 units.
• Warrants are exercisable immediately upon completion of the rights offering and expire five years later.
• The warrants are subject to redemption by the company at $0.01 per share under certain conditions.
• An over-subscription right allows shareholders who fully exercise their basic rights to purchase additional units not subscribed by others.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive as it is a necessary step for the company to raise capital, but it also carries the risk of dilution for existing shareholders. The inclusion of warrants adds a potential upside.

Positives

• The rights offering provides existing shareholders the opportunity to purchase additional shares at a potentially discounted price.
• The inclusion of warrants in each unit could provide additional upside potential for investors.
• The over-subscription right allows shareholders to increase their stake if other shareholders do not fully participate.
• The company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets.

Negatives

• The rights offering could dilute existing shareholders' ownership if they do not participate.
• The warrants are subject to redemption by the company under certain conditions, which could limit their potential value.
• The final subscription price is uncertain as it depends on the volume-weighted average price of the common stock.

Risks

• The success of the rights offering is not guaranteed, and the company may not raise the full $60 million.
• The company's future fundraising efforts may not be successful.
• The company's CellFX nsPFA technology may not achieve commercial success.
• The company's operations may be impacted if the rights offering is not successful.

Future Outlook

The company's future fundraising efforts and the success of the rights offering are uncertain, and the company's operations may be impacted if the rights offering is not successful. The company is focused on the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets.

Management Comments

• Pulse Biosciences is committed to health innovation that has the potential to improve the quality of life for patients.

Industry Context

The rights offering is a common method for companies to raise capital, particularly in the biotechnology sector. Pulse Biosciences is leveraging its novel CellFX nsPFA technology, which is a unique approach in the bioelectric medicine field.

Comparison to Industry Standards

• Rights offerings are a common method for biotech companies to raise capital, especially when they are in the development stage and require funding for clinical trials and commercialization.
• Comparable companies in the bioelectric medicine space, such as Medtronic and Boston Scientific, often use a mix of debt and equity financing to fund their operations and research.
• The terms of the rights offering, including the unit price and warrant structure, are fairly standard for this type of financing in the biotech industry.
• The potential for dilution is a common concern for shareholders in rights offerings, and Pulse Biosciences is no exception.

Stakeholder Impact

• Shareholders have the opportunity to purchase additional shares at a potentially discounted price, but face potential dilution if they do not participate.
• The company's employees may be impacted by the success or failure of the rights offering.
• The company's customers and suppliers may be impacted by the company's ability to continue operations and develop its technology.

Next Steps

• Shareholders must decide whether to exercise their subscription rights before the expiration date of June 26, 2024.
• The company will determine the final subscription price based on the volume-weighted average price of the common stock.
• The company will complete the rights offering and issue the units to participating shareholders.

Key Dates

Keywords

rights offering, Pulse Biosciences, CellFX, nsPFA, warrants, subscription rights, capital raise, bioelectric medicine, atrial fibrillation